Antibody Information
General Information of This Antibody
| Antibody ID | ANI0AKOIB |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | PF-06478924 |
|||||
| Synonyms |
RN926
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | Tumor-associated calcium signal transducer 2 (TACSTD2) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
PF-06664178 [Terminated in phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
0.00%
|
|||
| Patients Enrolled |
Advanced solid tumors resistant to standard therapy, or for which no other therapy was available, and at least one measurable lesion defined by Response Evaluation Criteria in Solid Tumors (RECIST version 1.1).
|
||||
| Administration Dosage |
Once every 21 days as an intravenous infusion over approximately 60 min, doses starting from 0.15 mg/kg to 6.14 mg/kg.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02122146 | Clinical Status | Phase 1 | ||
| Clinical Description |
A phase 1, dose escalation study of Pf-06664178 in patients with locally advanced or metastatic solid tumors.
|
||||
| Primary Endpoint |
In the 29 response-evaluable patients,the best overall response observed was limited to stable disease (SD) in 11 patients(37.90%) with PR or CR.
|
||||
| Other Endpoint |
Doses explored ranged from 0.15 mg/kg to 4.80 mg/kg. Doses of 3.60 mg/kg,4.20 mg/kg and 4.80 mg/kg were considered intolerable due to DLTs. MTD and RP2D were not determined.
|
||||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.